Other Events ·
Telix Pharmaceuticals completed enrollment in its Phase 3 BiPASS study on September 2, 2026, recruiting 350 patients…
TLPPFTelix Pharmaceuticals Ltd
Telix Pharmaceuticals completed enrollment in its Phase 3 BiPASS study on September 2, 2026, recruiting 350 patients to evaluate the diagnostic performance of Illuccix and Gozellix for prostate cancer imaging prior to biopsy. The company also aligned with the FDA on a New Drug Application pathway that could support reimbursement and broaden access to its PSMA-PET agents. Telix Pharmaceuticals is a commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer diagnosis and treatment.